Categories: Wire Stories

Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI

MINNEAPOLIS–(BUSINESS WIRE)–#EPeepsImricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare.


Under the terms of the MOU, GE HealthCare and Imricor intend to collaborate to interface Imricor�s Advantage-MR EP Recorder/Stimulator and Northstar-MR 3D Mapping System with GE HealthCare MRI scanners. A successful collaboration will enable cardiac electrophysiology (EP) ablation procedures guided by real-time MRI, using Imricor’s catheters and other disposable devices, to be performed on the GE HealthCare MRI platform. The collaboration with GE HealthCare would expand Imricor’s potential to interface with GE HealthCare’s new and currently installed MRI scanners.

Imricor’s short-term goal is to allow sites with GE HealthCare MRI systems to participate in the upcoming “Vision-MR Ablation of Atrial FLutter” or VISABL-AFL clinical trial in the US and “Vision-MR Ablation of Ventricular Tachycardia” or VISABL-VT clinical trial in Europe. The Company’s overall goal is to broaden in the choices physicians and hospitals have when choosing an MRI platform for their iCMR labs.

“Imricor’s innovative technology has the potential to bring significant benefit to a large number of cardiac arrhythmia patients,” said Anja Brau, PhD, General Manager, GE HealthCare MR Clinical Solutions and Research Collaborations. “GE HealthCare has a long-standing history of applying MR to therapy guidance and control; we would be pleased to add Imricor’s capabilities to provide our customers with more options to treat their patients.”

“We are thrilled at the prospect of expanding the portfolio of MRI scanners that support Advantage-MR and Northstar-MR technology,” said Steve Wedan, Imricor’s CEO and Chair. “The addition of GE HealthCare will give physicians and hospitals significantly more flexibility to use the MRI hardware of their choice, when providing real-time iCMR ablations for their patients. We are grateful to our existing customers who have embraced our real-time iCMR ablation technology, and look forward to making the benefits of this technology even more widely available.”

About Imricor

Please visit http://imricor.com/investors/about-imricor/ for more information about Imricor, Foreign Ownership Restrictions, and Forward-Looking Statements.

Contacts

Nick Twohy

Vice President of Marketing, Imricor

Email: nick.twohy@imricor.com
Phone: +1 952 818 8407

Alex

Recent Posts

Capstone Copper Announces 2024 Annual General and Special Meeting Results

VANCOUVER--(BUSINESS WIRE)--Capstone Copper Corp. (“Capstone” or the “Company”) (TSX:CS) (ASX:CSC) announced the voting results from…

8 hours ago

Indonesia International Remittance Market Growth and Future Opportunities 2024-2028: Rising Transaction Values and Volumes Characterize the Landscape – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Indonesia International Remittance Market Business and Investment Opportunities - Analysis by Transaction Value…

8 hours ago

KCAS Bio and Crux Biolabs Announce Global Spectral Flow Cytometry Alliance

KCAS Bio continues to expand its global reach and has selected Crux Biolabs (Melbourne, Australia)…

14 hours ago

Firstsource Acquires Quintessence

Strengthens end-to-end RCM offering to healthcare providers Expands service capabilities to US physicians’ practices, and…

15 hours ago

UPCX Becomes the Main Sponsor for Coinfest Asia 2024

SINGAPORE - Media OutReach Newswire - 3 May 2024 - UPCX (UPC), a developer of…

15 hours ago

China Biological Reagents (Molecular Biology Reagents, Proteins and Cell Reagents) Industry Research 2023-2024 & 2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "China Biological Reagents Market (Molecular Biology Reagents, Proteins and Cell Reagents): Insights &…

15 hours ago